A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma.

Tomer M Mark,Danielle Guarneri,Peter Forsberg,Adriana Rossi,Roger Pearse,Arthur Perry,Karen Pekle, Linda Tegnestam,June Greenberg,Tsiporah Shore,Usama Gergis,Sebastian Mayer,Koen Van Besien,Scott Ely,David Jayabalan,Daniel Sherbenou,Morton Coleman,Ruben Niesvizky

Biology of Blood and Marrow Transplantation（2017）

引用 10|浏览54

暂无评分

摘要

•The maximum tolerated dose of high-dose lenalidomide was not reached at 350 mg/day.•Pretransplantation conditioning with high-dose lenalidomide plus melphalan was well tolerated.•All trial participants achieved a response to the investigational treatment strategy.•Median progression-free and overall survival were 10 and 22 months, respectively.

查看译文

关键词

Lenalidomide,Melphalan,Autologous stem cell transplantation,Relapsed and refractory multiple myeloma

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要